Literature DB >> 6652350

Pharmacological mapping of regional effects in the rabbit heart of some new antiarrhythmic drugs.

J S Millar, E M Vaughan Williams.   

Abstract

In vitro preparations of rabbit heart were made from which measurements of effective refractory period (ERP), atrio-Hisian (A-H) and His-Purkinje (H-P) conduction times could be obtained, analogous to electrophysiological measurements customarily carried out in vivo. Intracellular potentials also were recorded from the sino-atrial (SA) node, atrium, bundle of His, preterminal Purkinje fibres and papillary muscles. The effects of a range of concentrations of three new antiarrhythmic drugs, melperone, cibenzoline and alinidine were compared, the lower concentrations studied corresponding to clinical levels. At low concentrations the effects of melperone, inducing bradycardia and lengthening ERP, could be attributed to prolongation of action potential duration (APD) in the sinus node and atrial and ventricular tissues. The slope of slow diastolic depolarization was not altered, nor was there any change in A-H or H-P conduction time, or in maximum rate of depolarization (MRD). At higher concentrations melperone had a substantial class 1 action, but there was no negative inotropic effect, or other evidence of restriction of slow inward current. Cibenzoline was primarily a class 1 agent but also lengthened APD to some extent in the SA node and in atrial and ventricular muscle, but not in Purkinje fibres. APD thus became more uniform along the ventricular conducting pathway. Cibenzoline also depressed contractions and increased A-H conduction time, implying restriction of slow inward current. The bradycardia could thus be attributed to a slowing of both depolarization and repolarization in the SA node, without any change in slope of the slow diastolic depolarization. Conduction time was increased in all tissues. 8 Alinidine greatly reduced the slope of the slow diastolic depolarization and slightly lengthened APD in the SA node. MRD was also reduced in the SA node, and A-H conduction time was increased, implying some restriction of slow inward current. However, there was no negative inotropic effect. 9 Alinidine had no significant effect on MRD in atrium, ventricle or Purkinje cells, nor was H-P conduction time altered, implying absence of effect on fast inward current. APD was moderately lengthened in atrium and ventricle but not in Purkinje cells. 10 It was concluded that the effects of the drugs in the sinus node and on ERP and on A-H and H-P conduction times could be accounted for by their selective cellular actions in different regions of the heart.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6652350      PMCID: PMC2044915          DOI: 10.1111/j.1476-5381.1983.tb10007.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  13 in total

1.  Mexiletine in isolated tissue models.

Authors:  E M Williams
Journal:  Postgrad Med J       Date:  1977       Impact factor: 2.401

2.  Anti-arrhythmic action of melperone in the dog heart in situ.

Authors:  E S Platou; H Refsum; J P Amlie; K Landmark
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1979-02

3.  Dual effect of disopyramide on atrial and atrioventricular conduction and refractory periods.

Authors:  J S Birkhead; E M Vaughan Williams
Journal:  Br Heart J       Date:  1977-06

4.  Electrophysiological effects of lidocaine on distal Purkinje fibers of canine heart.

Authors:  J Wittig; L A Harrison; A G Wallace
Journal:  Am Heart J       Date:  1973-07       Impact factor: 4.749

5.  Electrophysiological propertiesf the canine peripheral A-V conducting system.

Authors:  R J Myerburg; J W Stewart; B F Hoffman
Journal:  Circ Res       Date:  1970-03       Impact factor: 17.367

6.  Influence of beta-adrenergic and cholinergic blockade on the electrophysiological effects of melperone in the dog heart in situ.

Authors:  E S Platou; H Refsum; J P Amlie; K Landmark
Journal:  Cardiovasc Res       Date:  1981-03       Impact factor: 10.787

7.  Electrophysiological effects of melperone in the dog heart in situ - a new antiarrhythmic drug.

Authors:  H Refsum; J P Amlie; E S Platou; T Owren; K Landmark
Journal:  Cardiovasc Res       Date:  1981-03       Impact factor: 10.787

8.  Effects on rabbit nodal, atrial, ventricular and Purkinje cell potentials of a new antiarrhythmic drug, cibenzoline, which protects against action potential shortening in hypoxia.

Authors:  J S Millar; E M Vaughan Williams
Journal:  Br J Pharmacol       Date:  1982-03       Impact factor: 8.739

9.  Effects of alinidine, a novel bradycardic agent, on heart rate and blood pressure in man.

Authors:  D W Harron; K Jady; J G Riddell; R G Shanks
Journal:  J Cardiovasc Pharmacol       Date:  1982 Mar-Apr       Impact factor: 3.105

10.  Pacemaker selectivity: influence on rabbit atria of ionic environment and of alinidine, a possible anion antagonist.

Authors:  J S Millar; E M Williams
Journal:  Cardiovasc Res       Date:  1981-06       Impact factor: 10.787

View more
  8 in total

1.  Comparison of the cromakalim antagonism and bradycardic actions of a series of novel alinidine analogues in the rat.

Authors:  J L Challinor-Rogers; T K Hay; G A McPherson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-08       Impact factor: 3.000

Review 2.  Cibenzoline. A review of its pharmacological properties and therapeutic potential in arrhythmias.

Authors:  D W Harron; R N Brogden; D Faulds; A Fitton
Journal:  Drugs       Date:  1992-05       Impact factor: 9.546

3.  An investigation into the characteristics of reperfusion-induced arrhythmias in the anaesthetized rat and their susceptibility to antiarrhythmic agents.

Authors:  K A Kane; J R Parratt; F M Williams
Journal:  Br J Pharmacol       Date:  1984-06       Impact factor: 8.739

4.  The effects of the 5 HT2 antagonist ritanserin on blood pressure and serotonin-induced platelet aggregation in patients with untreated essential hypertension.

Authors:  D J Stott; A R Saniabadi; J Hosie; G D Lowe; S G Ball
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

5.  Cibenzoline attenuates systolic anterior motion of the mitral valve after mitral valvoplasty.

Authors:  Takeshi Omae; Akira Matsunaga; Naka Imakiire; Ryuzo Sakata; Yuichi Kanmura
Journal:  J Anesth       Date:  2009-08-14       Impact factor: 2.078

6.  Inhibition of the myocardial Ca2+ inward current by the class 1 antiarrhythmic agent, cibenzoline.

Authors:  M Holck; W Osterrieder
Journal:  Br J Pharmacol       Date:  1986-04       Impact factor: 8.739

7.  Effects on rabbit cardiac potentials of aprindine and indecainide, a new antiarrhythmic agent, in normoxia and hypoxia.

Authors:  P D Dennis; E M Vaughan Williams
Journal:  Br J Pharmacol       Date:  1985-05       Impact factor: 8.739

8.  Indoramin-prolongation of repolarization time, a mechanism of bradycardia in man?

Authors:  D W Harron; D P Nicholls; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1985-02       Impact factor: 4.335

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.